30,35MeV/u 36,40Ar＋112,124Sn反应中热核性质同位旋效应的实验研究

针对①中能反应中同位旋自由度是否达到平衡，②同位旋自由度对几中不同方法测量的核温度是否有影响 这两个基本问题，设计了用30和35MeV/u ~(36,40)Ar轰击~(112,124)Sn反应的实验方案。得到如下结果：对于前角5°处的耗散弹核碎裂产物，丰中子同位素与稳定核的产额比随产物出射动能的增加而减小，而丰质子子同位素与稳定核的产额比随动能的增加而增加，呈现明显的剪刀差分布特性。随耗散时间的增大，产物的平均中质比逐渐由弹核的平均中质比向系统的平均中质比过渡。这个结果说明在该反应中，同位旋自由度没有达到完全平衡。而对于20°处的DIC产物，上述剪刀差分布特性变得更不明显，这是同位旋自由度由非平衡向平衡过渡的表现。后角轻粒子的能谱分析表明，初始热核的同位旋会影响斜率核温度的提取，由于丰中子轻粒子~6He在~(40)Ar + ~(112)Sn系统中的蒸发被抑制，相比~(40)Ar + ~(112)Sn而言，其蒸发比较容易发生在衰变链早期，因此提取的温度偏高，同样，丰质子轻粒子~3He的温度在~(40)Ar + ~(112)Sn中略高。但中后角的同位素产额分析表明，反应系统的同位旋对双同位素比核温度几乎没有影响。核温度作为热核的热力学量，是独立于测量方法的，这种不同的方法得出的差异主要来源于同位旋对衰变机制的影响。作为一个尝试，将中高能反应中的熵的提取推广到这个能区，发现两个系统的熵几乎一致。在量子统计模型框架下，考察核温度与熵的关系发现，~(40)Ar + ~(112)Sn反应的挤出时刻密度略高于~(40)Ar + ~(112)Sn。

36单元塑料闪烁体陈列探测器制作与调试

本文描述了一个能在中解（10－100Mev/u）重离子核反应测量中鉴别轻粒子，测量粒子多重性，并能给出轻粒子能量和位置信息的大立体角（θ: 5°-20°φ: 0°-360°）的36单元塑料闪烁体陈列探测器的制作与调试，初步调试结果表明该探测器对轻粒子（p、α等）有较好的分辨。同时对国际上几种规模较大的先进的多单元大立体角粒子探测系统作了比较全面的介绍

Synthesis and characterization of the nanoporous ultrathin multilayer films based on molybdenum polyoxometalate (Mo-36)(n)

Ultrathin multilayer films of the wheel-shaped molybdenum polyoxometalate cluster (Mo-36)(n) and poly(allylamine hydrochloride) (PAH) have been prepared by the layer-by-layer (LbL) self-assembly method. The ((Mo-36)(n)/PAH)(m) multilayer films have been characterized by Xray photoelectron spectroscopy (XPS) and atomic force microscopy (AFM). UV-VIS measurements reveal regular film growth with each (Mo-36)(n) adsorption. The electrochemical behavior of the film at room temperature was investigated.

The chemistry of alpha-oxo ketene cyclic dithioacetal .36. Studies on silica G catalyzed decomposition of adducts of beta,beta-1,3-propylenedithio-alpha,beta-unsaturated arylketones with grignard reagents

beta, beta-1, 3-Piopylenedithio-alpha, beta-unsaturated arylketones 2 via chemoselective 1,2-addition with allyl or benzyl Grignard reagents afforded the corresponding carbinols 3 and 4. Catalysed by silica gel, the carbinols 3 and 4 were converted to the beta,gamma-unsaturated arylketones 5, 6. The mechanism and reaction condition were discussed.

Practice links [Issue 36, February 2010]

Practice Links is a free e-publication for practitioners working in Irish social services, voluntary and nongovernmental sectors. Practice Links was created to enable practitioners to keep up-to-date with new publications, electronic resources and conference opportunities. Issue 36 features articles on equine assisted personal development, the National Child Care Information System and a report on Fieldwork Training for Social Workers

Cinética de sobrevivencia de Rhizobium meliloti B - 36 sobre semilla preinoculada con diferentes adhesivos y coberturas

p.167-171

A comparative analysis of the SF-12 and the SF-36 among ischaemic heart disease patients.

This paper investigated whether the SF-12 could replace the SF-36 in the measurement of health status among ischaemic heart disease patients. The SF-36 and SF-12 were administered to 105 cardiac patients. The SF-36 summary scores were strongly correlated and similar to the SF-12 summary scores. Also, the SF-12 scores were as powerful as the SF-36 summary scores in discriminating between subgroups of patients categorized according to their self-reported health status or angina classification. It is suggested that when there is a need to collect routine information about cardiac patients' general physical and mental health, the SF-12 is preferable to the SF-36 because of its brevity and acceptability to patients.

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

Glucagon-like peptide-1(7-36)amide (GLP-1) possesses several unique and beneficial effects for the potential treatment of type 2 diabetes. However, the rapid in-activation of GLP-1 by dipeptidyl peptidase IV (DPP IV) results in a short half-life in vivo (less than 2 min) hindering therapeutic development. In the present study, a novel His(7)-modified analogue of GLP-1, N-pyroglutamyl-GLP-1, as well as N-acetyl-GLP-1 were synthesised and tested for DPP IV stability and biological activity. Incubation of GLP-1 with either DPP IV or human plasma resulted in rapid degradation of native GLP-1 to GLP-1 (9-36),amide, while N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 were completely resistant to degradation. N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 bound to the GLP-1 receptor but had reduced affinities (IC50 values 32(.)9 and 6(.)7 nM, respectively) compared with native GLP-1 (IC50 0(.)37 nM). Similarly, both analogues stimulated cAMP production with EC50 values of 16(.)3 and 27 nM respectively compared with GLP-1 (EC50 4(.)7 nM). However, N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 exhibited potent insulinotropic activity in vitro at 5(.)6 mM glucose (P

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo

Although the incretin hormone glucagon-like peptide-1 (GLP-1) is a potent stimulator of insulin release, its rapid degradation in vivo by the enzyme dipeptidyl peptidase IV (DPP IV) greatly limits its potential for treatment of type 2 diabetes. Here, we report two novel Ala(8)-substituted analogues of GLP-1, (Abu(8))GLP-1 and (Val(8) GLP-1 which were completely resistant to inactivation by DPP IV or human plasma. (Abu(8))GLP-1 and (Val(8))GLP-1 exhibited moderate affinities (IC50: 4.76 and 81.1 nM, respectively) for the human GLP-1 receptor compared with native GLP-1 (IC50: 0.37 nM). (Abu(8))GLP-1 and (Val(8))GLP-1 dose-dependently stimulated cAMP in insulin-secreting BRIN BD11 cells with reduced potency compared with native GLP-1 (1.5- and 3.5-fold, respectively). Consistent with other mechanisms of action, the analogues showed similar, or in the case of (Val(8))GLP-1 slightly impaired insulin releasing activity in BRIN BD11 cells. Using adult obese (ob/ob) mice, (Abu(8))GLP-1 had similar glucose-lowering potency to native GLP-1 whereas the action of (Val(8))GLP-1 was enhanced by 37%. The in vivo insulin-releasing activities were similar. These data indicate that substitution of Ala(8) in GLP-1 with Abu or Val confers resistance to DPP IV inactivation and that (Val(8))GLP-1 is a particularly potent N-terminally modified GLP-1 analogue of possible use in type 2 diabetes.